These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 33037161)

  • 1. Response to ixekizumab in a patient of psoriasis with secondary failure to secukinumab.
    Mittal S
    Indian J Dermatol Venereol Leprol; 2021; 87(1):119-121. PubMed ID: 33037161
    [No Abstract]   [Full Text] [Related]  

  • 2. The successful treatment with ixekizumab in a multi-failure psoriasis patient.
    Azevedo A; Torres T
    Dermatol Online J; 2018 Sep; 24(9):. PubMed ID: 30677837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term follow-up of 22 psoriatic patients treated with ixekizumab after failure of secukinumab.
    Amschler K; Phillip S; Mohr J; Wilsmann-Theis D; Poortinga S; Gerdes S; Mössner R
    Dermatol Online J; 2020 Jan; 26(1):. PubMed ID: 32155021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
    Bokor-Billmann T; Schäkel K
    J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
    Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
    J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. IL-17 inhibitors for psoriasis.
    Paek SY; Frieder J; Kivelevitch D; Menter MA
    Semin Cutan Med Surg; 2018 Sep; 37(3):148-157. PubMed ID: 30215631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of ixekizumab in patients with resistance or incomplete response to secukinumab.
    Hegazy S; Konstantinou MP; Bulai Livideanu C; Tauber M; Paul C
    J Eur Acad Dermatol Venereol; 2019 Sep; 33(9):e338-e341. PubMed ID: 31001858
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of Body Weight on Risk-Benefit and Dosing Regimen Recommendation of Secukinumab for the Treatment of Moderate to Severe Plaque Psoriasis.
    Lee JE; Wang J; Florian J; Wang YM; Kettl D; Marcus K; Woitach A
    Clin Pharmacol Ther; 2019 Jul; 106(1):78-80. PubMed ID: 31188469
    [No Abstract]   [Full Text] [Related]  

  • 9. First emergence of pyoderma gangraenosum, palmoplantar pustulosis and sacroiliitis in a psoriasis patient associated with switching from secukinumab to brodalumab.
    Sadik CD; Thieme M; Zillikens D; Terheyden P
    J Eur Acad Dermatol Venereol; 2019 Nov; 33(11):e406-e407. PubMed ID: 31131924
    [No Abstract]   [Full Text] [Related]  

  • 10. The Role of IL-17 in the Pathogenesis of Psoriasis and Update on IL-17 Inhibitors for the Treatment of Plaque Psoriasis.
    AbuHilal M; Walsh S; Shear N
    J Cutan Med Surg; 2016 Nov; 20(6):509-516. PubMed ID: 27207350
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of ixekizumab in a group of 16 elderly patients with psoriasis over a 1-year period.
    Megna M; Cinelli E; Balato A; Gallo L; Fabbrocini G
    J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):e152-e153. PubMed ID: 31715054
    [No Abstract]   [Full Text] [Related]  

  • 12. Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Kimura R; Sugita K; Yamamoto O
    Eur J Dermatol; 2020 Dec; 30(6):732-734. PubMed ID: 33237034
    [No Abstract]   [Full Text] [Related]  

  • 13. Paradoxical Arthritis Due to Ixekizumab in a Patient With Plaque Psoriasis.
    Vidal D; Ros S; Reina D
    Actas Dermosifiliogr (Engl Ed); 2019 Apr; 110(3):255-256. PubMed ID: 29861037
    [No Abstract]   [Full Text] [Related]  

  • 14. Response to IL-17A inhibitors secukinumab and ixekizumab cannot be explained by genetic variation in the protein-coding and untranslated regions of the IL-17A gene: results from a multicentre study of four European psoriasis cohorts.
    van Vugt LJ; van den Reek JMPA; Meulewaeter E; Hakobjan M; Heddes N; Traks T; Kingo K; Galluzzo M; Talamonti M; Lambert J; Coenen MJH; de Jong EMGJ
    J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):112-118. PubMed ID: 31287604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and safety of switching to ixekizumab in secukinumab nonresponder patients with psoriasis: results from a multicentre experience.
    Conti A; Peccerillo F; Amerio P; Balato A; Bardazzi F; Bianchi L; Burlando M; Cannavò SP; Chiricozzi A; Dapavo P; De Simone C; Fargnoli MC; Gambardella A; Gisondi P; Malagoli P; Malara G; Mugheddu C; Offidani AM; Piaserico S; Prignano F; Stingeni L; Pellacani G
    Br J Dermatol; 2019 Jun; 180(6):1547-1548. PubMed ID: 30578668
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical experience of ixekizumab in the treatment of patients with history of chronic erythrodermic psoriasis who failed secukinumab: a case series.
    Lo Y; Tsai TF
    Br J Dermatol; 2019 Nov; 181(5):1106-1107. PubMed ID: 31145806
    [No Abstract]   [Full Text] [Related]  

  • 17. Ixekizumab for the treatment of psoriasis: up-to-date.
    Craig S; Warren RB
    Expert Opin Biol Ther; 2020 Jun; 20(6):549-557. PubMed ID: 32050819
    [No Abstract]   [Full Text] [Related]  

  • 18. No reactivation of tuberculosis in patients with latent tuberculosis infection receiving ixekizumab: A report from 16 clinical studies of patients with psoriasis or psoriatic arthritis.
    Mrowietz U; Riedl E; Winkler S; Xu W; Patel H; Agada N; Lebwohl MG
    J Am Acad Dermatol; 2020 Nov; 83(5):1436-1439. PubMed ID: 32526319
    [No Abstract]   [Full Text] [Related]  

  • 19. Safety of secukinumab in psoriasis patients with latent tuberculosis infection.
    Machado Á; Abreu M; Torres T
    Eur J Dermatol; 2020 Dec; 30(6):740-741. PubMed ID: 33237033
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52-week, open-label, phase 3 study (UNCOVER-J).
    Saeki H; Nakagawa H; Nakajo K; Ishii T; Morisaki Y; Aoki T; Cameron GS; Osuntokun OO;
    J Dermatol; 2017 Apr; 44(4):355-362. PubMed ID: 27726163
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.